Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

发表于 2026-9-6 17:18:25

期刊：Medicina

文献作者：Shinsuke Suzuki; Satoshi Toyoma; Yohei Kawasaki; Koh Koizumi; Nobuko Iikawa; Kazuhiro Shiina; Tentaro Endo; Tomoe Abe; Teppei Kouga; Takechiyo Yamada

出版日期：--

DOI号：10.3390/medicina57111151

下载链接：https://www.mdpi.com/1648-9144/57/11/1151/pdf

文献链接：https://doi.org/10.3390/medicina57111151

当前文献来源于 MDPI AG。

备注信息：

发表于 2026-9-6 17:18:26

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[MDPI] Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[MDPI] Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 一键复制